What is the CVR number of MC2 Therapeutics A/S?

MC2 Therapeutics A/S is registered with CVR / Virk under CVR 29526346.

What is the revenue of MC2 Therapeutics A/S?

MC2 Therapeutics A/S reported revenue of DKK 24,5M in 2024.

MC2 Therapeutics A/S employs 11 people as of the latest annual report.

Mads Jørgen Nøhr Clausen chairs the board of MC2 Therapeutics A/S, in role since 2017.

MC2 Therapeutics A/S's registered address is Agern Alle 24-26.

A/SActive

CVR 29526346Agern Alle 24-26, 2970 HørsholmManufacture of pharmaceutical preparations· NACE 2120Est. 2006 · 20 years old11 employees

Actively employed in the business

Name	Role	Member since
Current (2)
TA Trine Ahlgreen Management	Management	2025
JJ Jesper Jørn Lange Founder	Founder	2006
Former (2)
AM Anette Merete Nøhr Clausen Management	Management	2006 – 2006
SS Steen Sindet-Pedersen Management	Management	2006 – 2006

Non-executive oversight

Name	Role	Member since
Current (4)
TD Tomas Dahl Mikkelsen Board of Directors	Board of Directors	2023
AD Anders Dahlgaard Hove Board of Directors	Board of Directors	2017
JS John Sørensen Haurum Board of Directors	Board of Directors	2023
MJ Mads Jørgen Nøhr Clausen Chairman	Chairman	2017
Former (2)
MV Mette Vagner Johannesen Board of Directors	Board of Directors	2017 – 2022
PL Paul Louis Berns Board of Directors	Board of Directors	2017 – 2020

As of last annual report

Shareholder	Type	Ownership	Votes	Since
Alsmark Invest II ApS	Company	33.33–49.99%	33.33–49.99%	2023
Selskabet af 4. april 2023 ApS	Company	33.33–49.99%	33.33–49.99%	2023
MC2 HOLDING ApS	Company	15–19.99%	15–19.99%	2018
INVESTERINGSSELSKABET AF 30.4.1992 ApS	Company	33.33–49.99%	33.33–49.99%	2019
November S.á.r.l.	Individual	33.33–49.99%	33.33–49.99%	2016
HOLDINGSELSKABET J.S.R. AF 1.11.83 ApS	Company	33.33–49.99%	33.33–49.99%	2019
FÆLLES INVEST 2 A/S	Company	10–14.99%	10–14.99%	2018
ALSMARK INVEST II ApS	Company	33.33–49.99%	33.33–49.99%	2014
LANC ApS	Company	5–9.99%	5–9.99%	2014

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.